Cargando…

S220: REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: A CIBMTR SUBGROUP ANALYSIS BY PRIOR TREATMENT

Detalles Bibliográficos
Autores principales:	Ahmed, Nausheen, Kambhampati, Swetha, Hamadani, Mehdi, Grover, Natalie, Shadman, Mazyar, Locke, Frederick, Gerson, James, Frank, Matthew J., Budde, L. Elizabeth, Wang, Michael, Hu, Zhen-Huan, Nunes, Ana, Dalton, David, Kloos, Ioana, Lee, Daniel, Xu, Hairong, Pasquini, Marcelo, Herrera, Alex F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Oral Sessions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428490/ http://dx.doi.org/10.1097/01.HS9.0000967792.43327.c1

Ejemplares similares

P1454: REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR THE TREATMENT OF RELAPSED OR REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL) IN THE UNITED STATES (US)
por: Locke, F., et al.
Publicado: (2022)

Repeated Infusions of Brexucabtagene-autoleucel in Relapsed/Refractory Mantle Cell Lymphoma
por: Aydilek, Enver, et al.
Publicado: (2023)

Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma
por: Iacoboni, Gloria, et al.
Publicado: (2022)

Brexucabtagene autoleucel for mantle cell lymphoma, B-cell precursor acute lymphoblastic leukaemia
Publicado: (2023)

P1155: BREXUCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN ROUTINE PRACTICE: UPDATED REPORT FROM THE US LYMPHOMA CAR T CONSORTIUM
por: Wang, Y., et al.
Publicado: (2022)

Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton’s Tyrosine Kinase Inhibitor in Canada
por: Ball, Graeme, et al.
Publicado: (2022)

S312: IS BREXUCABTAGENE AUTOLEUCEL A COST-EFFECTIVE TREATMENT FOR REFRACTORY/RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA? A PHARMACOECONOMIC ANALYSIS IN THE PERSPECTIVE OF THE PUBLIC HEALTHCARE SYSTEM.
por: Marchetti, Monia
Publicado: (2023)

ASTCT, CIBMTR and EBMT Clinical Practice recommendations for transplant and cellular therapies in mantle cell lymphoma.
por: Munshi, Pashna N., et al.
Publicado: (2021)

P1391: VARNIMCABTAGENE AUTOLEUCEL (VAR-CEL) IN RELAPSED/ REFRACTORY CD19+ NON-HODGKIN LYMPHOMA
por: Martinez-Cibrian, Nuria, et al.
Publicado: (2023)

Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
por: Shah, Bijal D, et al.
Publicado: (2023)

Pattern of brexucabtagene autoleucel-related neurotoxicity on magnetic resonance imaging of the brain in a patient with relapsed/refractory B-cell acute lymphoblastic leukemia and prior leptomeningeal disease
por: Dean, Erin A., et al.
Publicado: (2023)

P367: LONG-TERM OUTCOMES OF ADULTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH BREXUCABTAGENE AUTOLEUCEL IN ZUMA-3 BY AGE, PRIOR THERAPIES, AND SUBSEQUENT TRANSPLANT
por: Shah, Bijal, et al.
Publicado: (2023)

Relmacabtagene autoleucel (relma‐cel) CD19 CAR‐T therapy for adults with heavily pretreated relapsed/refractory large B‐cell lymphoma in China
por: Ying, Zhitao, et al.
Publicado: (2020)

NMDP/CIBMTR donor selection guidelines
Publicado: (2019)

P28 EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER EXPOSURE TO NON-CELLULAR ANTI-B-CELL MATURATION ANTIGEN (BCMA) IMMUNOTHERAPY
por: van de Donk, N., et al.
Publicado: (2023)

ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR NEUROBLASTOMA: THE CIBMTR EXPERIENCE
por: Hale, Gregory A., et al.
Publicado: (2013)

COVID-19 in Hematopoietic Cell Transplant Recipients: A CIBMTR Study
por: Sharma, Akshay, et al.
Publicado: (2021)

Mar cel Levi
por: Baltesen, Frits
Publicado: (2021)

S262: SAFETY AND EFFICACY OF OBECABTAGENE AUTOLEUCEL (OBE-CEL), A FAST-OFF RATE CD19 CAR IN RELAPSED/REFRACTORY ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA:TOP LINE RESULTS OF THE PIVOTAL FELIX STUDY
por: Roddie, Claire, et al.
Publicado: (2023)

CompTIA A+: exams A+ essentials (220-601), 220-602, 220-603, 220-604
por: Brooks, Charles J, et al.
Publicado: (2008)

B09 CARTITUDE-2 COHORT B 18-MONTH FOLLOW-UP: CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH MULTIPLE MYELOMA (MM) AND EARLY RELAPSE AFTER INITIAL THERAPY
por: Zweegman, S., et al.
Publicado: (2023)

COVID-19 in Pediatric Hematopoietic Cell Transplant Recipients: A CIBMTR Study
por: Bhatt, Neel S., et al.
Publicado: (2021)

Safety and efficacy of letetresgene autoleucel alone or with pembrolizumab for relapsed/refractory multiple myeloma
por: Nishihori, Taiga, et al.
Publicado: (2022)

Pathogenic Carboxyl Ester Lipase (CEL) Variants Interact with the Normal CEL Protein in Pancreatic Cells
por: Dalva, Monica, et al.
Publicado: (2020)

Age is no Barrier for Adults undergoing HCT for AML in CR1: Contemporary CIBMTR Analysis
por: Maakaron, Joseph E., et al.
Publicado: (2022)

Unfavorable transcriptome profiles and social disadvantage in hematopoietic cell transplantation: a CIBMTR analysis
por: Taylor, Mallory R., et al.
Publicado: (2023)

CompTIA A+ 220-901 and 220-902
por: Prowse, David L
Publicado: (2016)

CompTIA A+ 220-801 and 220-802
por: Prowse, David L
Publicado: (2013)

CompTIA A+: 220-701 and 220-702
por: Prowse, David L
Publicado: (2011)

Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT
por: DeFilipp, Zachariah, et al.
Publicado: (2016)

CompTIA A+ practice questions: essentials, exams 220-602, 220-603, 220-604
por: Brooks, Charles J
Publicado: (2008)

Expression, Characterization and Synergistic Interactions of Myxobacter Sp. AL-1 Cel9 and Cel48 Glycosyl Hydrolases
por: Ramírez-Ramírez, Norma, et al.
Publicado: (2008)

Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis
por: Murthy, Hemant S., et al.
Publicado: (2023)

Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies
por: Cohen, Adam D., et al.
Publicado: (2022)

Population‐based cellular kinetic characterization of ciltacabtagene autoleucel in subjects with relapsed or refractory multiple myeloma
por: Wu, Liviawati S., et al.
Publicado: (2022)

CompTIA A+ 220-901 and 220-902 cert guide
por: Soper, Mark Edward
Publicado: (2017)

CompTIA A+ 220-901 and 220-902: cert guide
por: Soper, Mark Edward
Publicado: (2017)

CompTIA A+ 220-701 and 220-702 cert guide
por: Soper, Mark Edward, et al.
Publicado: (2011)

CompTIA A+ 220-701 and 220-702 practice questions
por: Regan, Patrick E
Publicado: (2011)

CompTIA A+ quick reference (220-701, 220-702)
por: Conry, Ben
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_263p6s6e76ts30o49uu65h3cop